Natixis Advisors LLC Buys Shares of 22,536 Dynavax Technologies Co. (NASDAQ:DVAX)

Natixis Advisors LLC acquired a new position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 22,536 shares of the biopharmaceutical company's stock, valued at approximately $288,000.

Several other institutional investors also recently modified their holdings of DVAX. Smartleaf Asset Management LLC increased its stake in Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 2,034 shares during the period. GAMMA Investing LLC grew its stake in shares of Dynavax Technologies by 55.1% in the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company's stock valued at $52,000 after purchasing an additional 1,457 shares during the period. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new position in shares of Dynavax Technologies in the 4th quarter worth approximately $71,000. Nisa Investment Advisors LLC lifted its position in shares of Dynavax Technologies by 19.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company's stock worth $83,000 after buying an additional 1,076 shares during the period. Finally, KBC Group NV boosted its stake in Dynavax Technologies by 68.7% in the 4th quarter. KBC Group NV now owns 7,016 shares of the biopharmaceutical company's stock valued at $90,000 after buying an additional 2,857 shares in the last quarter. Institutional investors and hedge funds own 96.96% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. William Blair reissued an "outperform" rating on shares of Dynavax Technologies in a report on Friday, February 21st. The Goldman Sachs Group cut shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. HC Wainwright reaffirmed a "buy" rating and set a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st. Finally, StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a report on Monday, February 24th.

Remove Ads

Dynavax Technologies Price Performance

NASDAQ DVAX traded up $0.16 on Wednesday, hitting $12.87. 1,688,905 shares of the company were exchanged, compared to its average volume of 2,137,959. Dynavax Technologies Co. has a 1-year low of $9.74 and a 1-year high of $14.63. The firm has a 50 day moving average of $13.37 and a two-hundred day moving average of $12.53. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.60 billion, a P/E ratio of 71.50 and a beta of 1.23.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting the consensus estimate of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. On average, equities analysts predict that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.